ABSTRACT
INTRODUCTION
Whole-brain radiation therapy (WBRT) has long been a mainstay in the treatment of brain metastases. The role of WBRT is to control radiologically visualized tumors as well as nonvisualized micrometastases. Stereotactic radiosurgery is a method of delivering high doses of focal irradiation to a tumor while minimizing the irradiation to the adjacent normal tissue [1, 2] . Beginning in the 1990s, it has come to be increasingly used worldwide for patients with no more than a few brain metastases. A recent prospective randomized trial from the Radiation Therapy Oncology Group (RTOG) showed a small but significant improvement in the survival of patients that had up to 3 metastases with good prognostic factors when SRS was used in conjunction with WBRT [2] .
However, WBRT has several adverse effects. Acute adverse effects include nausea and headache, but they are generally limited in severity and duration. On the other hand, the late adverse effects are severe, progressive, and irreversible. They are caused by a syndrome called leukoencephalopathy, which is a structural alteration of cerebral white matter in which myelin suffers the most damage. Mild cases are typified by a chronic confusional state with inattention, memory loss, and emotional dysfunction. More severe cases produce major neurologic sequelae such as dementia, abulia, stupor, and coma.
These symptoms usually develop 6-24 months after cranial radiation. The degree of neurotoxicity resulting from WBRT correlates with the total dose received and with the time-dose-fractionation scheme [3] . Because of the concern about leukoencephalopathy resulting from WBRT, treatment strategies relying on SRS alone have been increasingly used [4] [5] [6] [7] . On the other hand, it has been pointed out that the omission of WBRT from the initial brain management results in a significant increase in brain tumor recurrence [6, 7] . It is noteworthy that Regine et al. reported that brain tumor recurrence could also be a cause of neurocognitive functional deterioration [8] .
The current study from the Japanese Radiation Oncology Study Group Protocol 99-1 (JROSG 99-1) is the first prospective randomized trial comparing SRS alone and WBRT combined with SRS. The details of the results have been published elsewhere [1] . In brief, it was a multi-institutional prospective randomized trial comparing WBRT+SRS and SRS alone conducted in Japan between 1999 and 2003. Patients were randomized to receive WBRT+SRS (65 patients) or SRS alone (67 patients) for brain metastases. The primary endpoint was survival. No significant difference between the groups was observed in Aoyama H et al. 7 survival or cause of death; however, patients in the SRS-alone group experienced brain tumor recurrence significantly more frequently than those in the WBRT+SRS group. No difference in the functional observation rate (Karnofsky Performance Status; KPS => 70) was observed.
We also monitored neurocognitive function serially by the Mini-Mental Score Examination (MMSE) [8] [9] [10] [11] [12] . Herein, we present the results of detailed analysis of neurocognitive function for this trial. This is the first report to compare neurocognitive function in patients receiving either SRS alone or WBRT+SRS.
MATERIALS AND METHODS

Randomization and Treatment
Eligible patients had 1-4 brain metastases detected on enhanced MRI, each less than 3 cm, and good systemic performance status (KPS of 70 or more).
A total of 132 patients were randomized to receive WBRT+SRS (65 patients) or SRS alone (67 patients) for brain metastases. Written informed consent was obtained from each patient before entry into the study. Randomization was performed at the Hokkaido University Hospital Data Center. A permuted-blocks randomization algorithm was used with a block size of 4. A randomization sheet was created for each institution. Prior to randomization, the patients were stratified based on the following criteria: number of brain metastases (single vs.
2-4), extent of extracranial disease (active vs. stable), and primary tumor site (lung vs. other sites). The extracranial disease was considered to be stable when the tumor had been clinically controlled for 6 months or longer prior to the detection of brain metastases. The WBRT schedule was 30 Gy in 10 fractions over 2 to 2.5 weeks. WBRT proceeded to SRS in patients assigned to the WBRT+SRS group. The SRS dose was prescribed to the tumor margin.
Metastases with a maximum diameter of up to 2 cm were treated with 22-25 Gy, and those larger than 2 cm were treated with 18-20 Gy. The dose was reduced by 30% when the treatment was combined with WBRT [1] .
Assessment of neurocognitive function
Neurocognitive function was assessed by the MMSE [8] [9] [10] [11] [12] . The MMSE is a short, standardized tool to grade cognitive function. The examination begins with an assessment of orientation to place and time. A maximum of 10 points can be obtained in this section. A test of memory has the subject immediately repeat the name of three objects presented orally. The subject then subtracts sevens serially from 100 and is subsequently asked to recall the three items previously repeated. The final section evaluates aphasia and apraxia by testing naming, repetition, compliance with a three-step command, comprehension of written words, writing, and copying a drawing, for a total of 9 points in this section. The maximum score that can be obtained for the entire MMSE is 30 points [10] [11] [12] . For the analysis of post-treatment change in MMSE, patients for whom no follow-up MMSEs were available were excluded. A statistically meaningful change is defined as a three-point change in MMSE score [8, 12] . While this criterion is felt to be potentially less conservative, due to the possibility of missing a "meaningful" change in MMSE score [13] , it may be a more reliable change Aoyama H et al. 10 index [8, 12] . In addition, a score of 26 or less was defined as abnormal [8] . MRI findings regarding leukoencephalopathy were also assessed according to the criterion in NCI-CTC version 2.0 and correlated to the change in MMSE score [14] . Tumor progression was scored when there was an increase in tumor size of at least 25%, based on the measurement of perpendicular diameters [1] .
Statistical analysis
The MMSE score was summarized as an average. Due to a ceiling effect and the clustering of values at 30, the data were not normally distributed.
The Wilcoxon rank-sum test was used to compare the means. The χ 2 test was used to determine the relationship between two categorical variables, and the Fisher exact test was used when small cell sizes were encountered in 2 x 2 contingency tables. Univariate analyses were carried out by the Kaplan and
Meier method, and we used the log-rank test to compare differences between the groups. A two-sided P value of less than or equal to 0.05 was considered to reflect statistical significance. All statistical analyses were initially performed by a physician (HA) using a commercial statistical software package (StatView 5.0J; SAS Institute Inc., Cary, NC, USA), and all results were verified by a statistician Aoyama H et al. 11 (GK) using a different software package (SAS version 9.1; SAS Institute Japan Ltd., Tokyo, Japan).
RESULTS
Baseline MMSE
The pre-treatment MMSE was obtained in 99 patients. MMSE data during the treatment were obtained in 11 additional patients. Those data, from 110 of 132 (83%) patients enrolled the study, constituted the "baseline" MMSEs and were used for the analysis (Figure 1) . The characteristics of those 110 patients are listed in Table 1 by treatment group. There was no statistically significant difference between the groups. A comparison of MMSE according to the patients' characteristics is summarized in Table 2 Although the difference was not significant by the log-rank test (P=0.79), the separation of the two curves between 12 and 24 months became wider than that in Figure 2a . The average duration until deterioration was 16.5 months (median, who enrolled in RTOG 91-04 [8] . They found that control of the brain tumor has a significant impact on the maintenance of MMSE scores. At 3 months, the average change in MMSE score was a drop of 0.5 for those whose brain metastases were radiologically controlled, as compared to a drop of 6.3 for those with uncontrolled brain metastases (p=0.02). One of the shortcomings of this report was that they evaluated the change in MMSE only at 3 months after brain treatment; therefore, the long-term effect of WBRT was not fully investigated. In the current study, we revealed some important factors that might affect a patient's baseline MMSE. The number of brain metastases was not a significant factor affecting baseline MMSE, but tumor volume (3 cc or more) and degree of edema (half of a hemisphere or more) were significant factors. More importantly, 51% of patients who had MMSE scores of 27 or less experienced significant improvement of MMSE at a median of 2.7 months after the treatment, regardless of which treatment they received initially. This finding supports the findings reported by Murray et al. [9] .
Another important finding of the current study was the continuous drop in MMSE in patients who received WBRT initially, although WBRT was not a cause of neurocognitive deterioration for the majority of brain metastatic patients.
Patients who received WBRT combined with SRS experienced stable MMSE for approximately 2 years after treatment, perhaps due to the preventative effect on brain tumor recurrence compared with the SRS-alone group. Considering that the median survival of patients with brain metastases is around 7 months, this prevention effect when WBRT is included in the initial management is beneficial in the majority of brain metastatic patients. Nevertheless, the continuous deterioration of neurocognitive function for long-term survivors receiving WBRT could not be neglected.
In addition, MRI findings suggested leukoencephalopathy was useful only for patients who experienced severe neurocognitive dysfunction, and most patients who had Grade 1-2 radiological leukoencephalopathy did not show clinically meaningful signs of neurocognitive dysfunction as assessed by MMSE was used for the assessment. This is consistent with findings by Fujii O et al. [15] .
They evaluated the white matter changes on MRI following WBRT in 24 patients.
Whereas 12 patients (50%) developed radiological Grade 3 (large confluent areas) or more leukoencephalopathy, only 6 of these 12 patients showed clinical abnormalities such as dementia, depression, and speech impairment. However, the true incidence of neurocognitive deterioration is not well understood. In patients with small cell carcinoma of the lung whose primary tumor is in complete remission, prophylactic cranial irradiation (PCI) using WBRT is becoming a standard treatment [16] . Van with two tests in 22%, with three tests in 25%, and with all four tests in 7% [19] .
These findings indicate that WBRT frequently accompanies neurocognitive impairment in long-term survivors.
Clearly, while our findings are of interest, our report is not without limitations. First, we did not monitor the use of corticosteroid, which could be potentially influential to neurocognitive function. Second, we used MMSE as the sole measurement of neurocognitive function; however, MMSE has been criticized for having low specificity and sensitivity [20] . Recently, the Radiation Therapy Oncology Group started to use a "neurocognitive battery" of several assessment tools [21] [22] [23] [24] . Mehta et al. suggested that this battery is feasible for use in clinical trials and could detect small changes in neurocognitive function Aoyama H et al. 21 that MMSE alone could not detect [21, 22] . Nevertheless, we believe the present findings are valuable and that MMSE is still a useful tool to examine neurocognitive function in trials in which neurocognitive function is not the primary endpoint. There is no established effective treatment for neurocognitive deterioration after WBRT. Recently, Shaw EG et al. reported that donepezil, a drug developed for Alzheimer's disease, has a positive effect on cognitive function; however, further investigation is necessary to establish this drug's potential role in relation to WBRT [25] .
In conclusion, the current study revealed that the control of brain tumors is the most important factor in stabilizing neurocognitive function for the majority of brain metastatic patients. However, the long-term adverse effect on neurocognitive function may not be negligible. Therefore, the development of a means to identify those patients who are less likely to experience brain tumor recurrence, as well as further investigation to establish an optimal schedule of WBRT when combined with SRS, would be important steps toward the refinement of the treatment of brain metastases. 
